Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1826]

Olaparib improves disease-free survival in high-risk early-stage HER2-negative...

Prof Andrew Tutt - Institute of Cancer Research, London, UK

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations ( Prof Andrew Tutt - Institute of Cancer Research, London, UK )

Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients...

Prof Ravi Salgia - City of Hope, Duarte, USA

Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients with RAS-addicted solid cancers ( Prof Ravi Salgia - City of Hope, Duarte, USA )

CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 cycles chemo in aNSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II...

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Cemiplimab plus ipilimumab for advanced NSCLC

Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea

Cemiplimab plus ipilimumab for advanced NSCLC ( Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea )

Real world data and diagnostics in patients with NSCLC with EGFR exon 20...

Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio...

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions ( Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro )

OncoAlert and ecancer weekly roundup for March 01 - 06, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for March 01 - 06, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Changes in cancer patient management in India during the pandemic

Prof Geetu Bhandoria - Command Hospital, Kolkata, India

Changes in cancer patient management in India during the pandemic ( Prof Geetu Bhandoria - Command Hospital, Kolkata, India )

Promise of personalised medicine for patients with prostate cancer

Prof Eleni Efstathiou, Prof Alicia Morgans, Prof Karim Fizazi and Prof Gerhardt...

Promise of personalised medicine for patients with prostate cancer ( Prof Eleni Efstathiou, Prof Alicia Morgans, Prof Karim Fizazi and Prof Gerhardt Attard )

New tools that can be used in clinical practice to make better decisions for...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

New tools that can be used in clinical practice to make better decisions for women with early breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

SEMS trial: result of a prospective, multi-institutional phase II clinical...

Dr Sia Daneshmand - University of Southern California, Los Angeles, USA

SEMS trial: result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma ( Dr Sia Daneshmand - University of Southern California, Los Angeles, USA )

Neo-adjuvant therapy and surgical decision making in breast cancer

Dr Mehra Golshan - Yale School of Medicine, New Haven, USA

Neo-adjuvant therapy and surgical decision making in breast cancer ( Dr Mehra Golshan - Yale School of Medicine, New Haven, USA )

More from ecancer